PHOENIX, Oct. 10 -- Vital Living, Inc. (BULLETIN BOARD: VTLV.OB) , today announced the appointment of Paul Leibowitz, Ph.D. as its new Chief Scientist. Dr. Leibowitz joins Vital Living with over 20 years of diversified experience in management, research and development, operations, and finance in the biotechnology and pharmaceutical industries. He reports to Brad Edson, Chairman and CEO, and Stuart Benson, President of Vital Living.
Dr. Leibowitz's vast experience in various aspects of our industry is a welcome addition to Vital Living's management team," said Stuart A. Benson, President of Vital Living. "His expertise will help enable us to move rapidly forward with our plans to incorporate FDA-approved drug delivery technology into the development of once-a-day, timed release nutraceuticals."
Dr. Leibowitz is President of Redding Consulting Group, Inc., in New York City, a consulting practice serving small-midsize companies needing assistance with strategic, operating and product development planning, and in accessing the capital markets. Paul has held various management positions in the past, including posts as Chief Scientific Officer of TSI Corporation which, at the time, was the world's fifth largest independent CSO. Dr. Leibowitz also served as Director, Molecular and Analytical Biology at Schering-Plough Corporation for ten years. He founded biotechnology at Schering-Plough, built the infrastructure for biotechnology programs in several areas, and led its growth into one of the industry's leading forces.
"I am very excited to join Vital Living a dynamic and growing company," said Leibowitz. "It is clear that I am joining a company primed for growth and success. I believe that my extensive background in science will be an important asset to the Company as it works to utilize pharmaceutical technology in developing more convenient, controlled-release nutraceuticals."
About Vital Living
Vital Living develops and markets evidence-based nutraceuticals, designed to be incorporated by physicians into a standard physician/patient program, and supported by a specially designed compliance regimen. The Company's initial area of focus was cardiovascular health, the leading health concern in America affecting 60 million consumers. Essentum(TM), currently undergoing clinical trials, is already being endorsed by the Arizona Heart Institute and prescribed throughout the United States. Vital Living also owns MAF Bionutritionals and the Christopher's Herb line of over 300 products. For more information, visit www.vitalliving.com.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward- looking statements, including the company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the company's product development partners, the ability of the company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.